Why GLP-1 Medications Work Differently in Women's Bodies

A conversation with my medical team this week circled back to something that still doesn't get enough attention: women and men don't respond to GLP-1 medications the same way.

The same dose doesn't produce the same blood levels. The same blood levels don't produce the same side effects. And someone else's experience on the same medication doesn't necessarily tell you anything about yours.

If you're a woman taking semaglutide or tirzepatide, this matters. Not because something is wrong with how you're responding, but because understanding your biology helps you navigate treatment more effectively.

The numbers tell a story

A meta-analysis of 47 clinical trials published in Diabetes Care found that women consistently saw greater weight loss on GLP-1 medications than men. This wasn't a small footnote buried in one study. It was a pattern across thousands of patients and multiple drugs.

A real-world study tracking 7,847 people with type 2 diabetes found the same thing. Women lost significantly more weight than men on GLP-1 medications. And here's what makes it interesting: the difference held up even after researchers adjusted for starting weight, which medication people were on, and the dose relative to body size.

That last point is important. Even when a 60 kg woman and a 100 kg man are technically getting the same dose-per-kilogram, she's still losing more weight. Something beyond simple math is going on.

A study of 483 adults on semaglutide or liraglutide found that women were nearly twice as likely to be what researchers call "hyper-responders," meaning they lost more than 15% of their body weight. Being female was one of the strongest independent predictors of that response.

Not the same dose

Here's something that caught even some of the physicians on my team off guard: women consistently end up with higher levels of active medication in their blood than men, even at the same dose.

When you and a man both inject 2.4 mg of semaglutide weekly, the drug doesn't behave the same way in both of your bodies.

Why? Women tend to weigh less, so the same dose spreads through less tissue. We have smaller blood volumes. And our livers and kidneys clear the drug more slowly per kilogram of body weight. The result is more medication circulating for longer.

A population pharmacokinetic analysis found that women had 32% higher drug exposure to liraglutide than men of the same body weight. That's not a rounding error. That's a third more medication in your system.

The dosing protocols for these medications were designed to work for populations. But populations include both men and women, and the "average" response often tilts toward male physiology because safety studies have historically underrepresented women. As Leslie Schrock has written about in HLTH, much of biomedical research has centered on male bodies, and diagnostic tools built on that foundation underperform for women.

This isn't unique to GLP-1 medications. But with these drugs being prescribed to millions of people, the gap is hard to ignore.

Where estrogen fits in

Something interesting emerges when we look at women across different life stages.

Research on GLP-1 and estrogen shows these two systems share overlapping pathways, particularly in how the body handles fat in tissue and the liver. They appear to use some of the same cellular signaling routes. In plain terms, they talk to each other.

In animal studies simulating menopause, liraglutide prevented weight and fat gain to a similar degree as estrogen replacement. The GLP-1 medication essentially picked up some of the metabolic slack that falling estrogen left behind, primarily by reducing food intake and improving how efficiently the body used what was eaten.

Clinical data supports the connection. A Mayo Clinic study presented at ENDO 2025 found that postmenopausal women on hormone therapy lost roughly 35% more weight on tirzepatide than those not taking hormones. Both groups lost weight. But the combination seemed to work better than either approach alone.

This finding lands differently now that the FDA has updated its guidance on hormone therapy. As of November 2025, the agency removed the long-standing black box warning from hormone replacement products and added age-specific guidance showing benefits when HRT is started within 10 years of menopause. FDA Commissioner Marty Makary called the original warning "one of the greatest mistakes in modern medicine."

For women in their late 30s to mid-50s navigating perimenopause, this is relevant. GLP-1 medications seem particularly effective at managing the visceral weight gain that accompanies falling estrogen. Some of my patients describe it as finally having a tool that matches what their changing biology is doing.

The trade-off

The greater weight loss in women comes with a catch.

Women report GI side effects more frequently. In trials, women reported adverse effects 28% more often than men on liraglutide, and 41% more often on dulaglutide. Our own clinical data at The Shift shows a similar pattern.

This isn't because women are more sensitive. It's the other side of that same pharmacology: if you're getting more active drug in your system at the same dose, you're going to feel more of its effects, wanted and unwanted.

The practical takeaway is simple. Women may benefit from slower dose increases and lower maintenance doses than what the standard protocols assume.

Beyond the scale

Weight loss isn't just a number. What you lose matters.

Our team discussed a concern worth naming: women may lose a greater proportion of muscle compared to men, especially at lower starting weights, higher doses, or with longer treatment. Muscle is the most metabolically active tissue in your body, and losing it has long-term consequences for everything from blood sugar regulation to bone health.

This is one reason I'm cautious about aggressive dose increases in women who are already responding well at a lower dose. Sometimes preserving your nutrition and your relationship with food matters more than chasing another few percentage points.

It's also why strength training and adequate protein are not optional additions to treatment. They're foundational. The medication creates metabolic space. What you do in that space determines whether you're losing fat while keeping muscle, or losing both.

For older women, this becomes critical. The risk of frailty means we might aim for a slightly higher maintenance weight to protect long-term function.

The missing data

Here's what frustrates me. We have solid evidence that women respond differently to these medications. We have research suggesting estrogen status matters. And yet most clinical trials still don't separate their results by menopausal status. Female representation in early-stage drug studies has been historically thin. Postmenopausal women remain a massive knowledge gap, despite being one of the largest groups actually taking these medications.

This connects to a pattern in women's health that investor Leslie Schrock has named clearly: the instinct to break women's health into separate, fundable pieces. But the GLP-1 response can't be pulled apart from estrogen status, body composition, life stage, bone health, or gallbladder function. It's one interconnected system. The parts don't work when you ignore the whole.

What to do with this

Understanding how these drugs work differently in your body isn't academic. It changes treatment.

Go slow. Women may need more gradual dose increases than standard protocols suggest. If you're dealing with significant nausea or other GI symptoms, your current dose may already be providing real metabolic benefit, even if it seems "low" compared to what someone else is taking.

Your maintenance dose may be lower. The dose that gets you to your goal and the dose that keeps you there aren't always the same. For many women, a lower maintenance dose provides solid results with fewer side effects.

Hormone status matters. If you're in perimenopause or beyond, addressing hormones alongside GLP-1 treatment may improve your response. This doesn't mean everyone needs hormone therapy, but it's worth discussing with your clinician, especially now that the regulatory landscape has shifted.

Protect your muscle. Prioritize strength training and protein. This matters for everyone on these medications, but the data suggests women face a higher risk of muscle loss.

Watch for specific risks. Premenopausal women who respond quickly and drop their calorie intake very low face elevated risk for gallstones. Adequate fat intake and gradual weight loss help.

Care designed for your biology

At The Shift Clinic, we build treatment plans that account for your specific biology. That means understanding how sex, age, hormonal status, and individual response patterns all shape what good care looks like for you.

If you're on a GLP-1 medication and the side effects feel like too much, it's worth asking whether your dose might be higher than you need. If the response isn't what you expected, other factors may be in play.

The medication gives you space. Understanding how your body processes that medication helps you use that space wisely.

Your biology isn't a male default with a female adjustment. It's its own system, with its own patterns. It deserves care built around what actually works for you.